110 results
CORRESP
FGEN
FibroGen Inc
30 Sep 14
Correspondence with SEC
12:00am
Agreements
AstraZeneca Agreements, page F-15
1. Please clarify here and in MD&A the specific nature of the revenue that was recognized and deferred during … on page 82 of the Registration Statement to clarify the specific nature of the revenue that was recognized and deferred under the AstraZeneca
8-K
EX-99.1
FGEN
FibroGen Inc
28 Jun 19
Regulation FD Disclosure
9:01am
nature of fibrosis Pamrevlumab is a human monoclonal antibody to CTGF Hypertension Vascular Remodeling CTGF ECM Deposition Cell Motility Cell Adhesion … FUNCTION
Pulmonary dysfunction in DMD is progressive and restrictive in nature and is one of the most common causes of morbidity and mortality in non
CORRESP
8vt6ntn75 1ner
23 Oct 14
Correspondence with SEC
12:00am
S-1
EX-10.24
kib6w4ew
1 Oct 14
IPO registration
12:00am
D
wefdczgh
10 Dec 14
$20M in equity, sold $20M, 1 investor
12:00am
DEFA14A
2f30oe
31 May 23
Additional proxy soliciting materials
9:00am
8-K
EX-99.1
nixj8kh5o4x 6ya2ev
20 Aug 21
Other Events
12:00am
10-Q
m91nb9zudn
12 May 15
Quarterly report
12:00am
S-1
EX-10.2
nb6xm hv0
1 Oct 14
IPO registration
12:00am
S-1
EX-10.28
2qwainwq
1 Oct 14
IPO registration
12:00am